ImmunityBio, Inc. (IBRX)

ImmunityBio Revenue

ImmunityBio had revenue of $51.24M in the quarter ending June 30, 2026, with 93.91% growth. This brings the company's total for the last twelve months to $165.79M, up 192.92% year-over-year. In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. That makes ImmunityBio the 18,850th largest company in the world by revenue and 2,999th in the United States.

• Revenue (ttm): $165.79M
• Revenue Growth: +192.92%
• P/S Ratio: 56.32
• Revenue / Employee: $239,931
• Employees: 691
• Market Cap: 9.34B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Product 112.98M 99.7%
• Other 306.00K 0.3%

By Geography

Chart

• United States 113.01M 99.8%
• Europe 278.00K 0.2%

Fiscal year ended Dec 31, 2025 See the full ImmunityBio breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	113.29M	98.54M	668.31%
Dec 31, 2024	14.75M	14.12M	2,270.58%
Dec 31, 2023	622.00K	382.00K	159.17%
Dec 31, 2022	240.00K	-694.00K	-74.30%
Dec 31, 2021	934.00K	329.00K	54.38%
Dec 31, 2020	605.00K	-1.60M	-72.52%
Dec 31, 2019	2.20M	2.16M	4,585.11%
Dec 31, 2018	47.00K	2.00K	4.44%
Dec 31, 2017	45.00K	1.00K	2.27%
Dec 31, 2016	44.00K	-192.00K	-81.36%
Dec 31, 2015	236.00K	-405.00K	-63.18%
Dec 31, 2014	641.00K	41.00K	6.83%
Dec 31, 2013	600.00K	-	-

Data Source: Fiscal.ai Last updated: Aug 4, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error